Locations Main Campus: Chesterfield, MO 63017   |   Locations
314-434-1500 314-434-1500   |   Contact Us
Locations Search Close Menu

Monoclonal Antibody Infusion Therapy for Outpatient Treatment of COVID-19

The current significant increase in COVID-19 cases has led to an unprecedented demand for monoclonal antibodies. Unfortunately, federal supply of Regeneron and Sotrovimab are extremely limited, and these therapies are being allocated on a weekly basis. Consequently, we are limiting qualifying conditions to those individuals who are at highest risk of hospitalization and death due to COVID-19 infection. As supply of monoclonal antibody therapy becomes more readily available, these criteria may be modified and any changes will be communicated accordingly.
Casirivimab/imdevimab and sotrovimab are investigational monoclonal antibodies used for the treatment of COVID-19 in non-hospitalized adults. They are potent antispike neutralizing monoclonal antibodies designed to mimic the body's natural immune response by binding to the receptor-binding domain of SARS-CoV-2. Monoclonal antibody (mAB) therapy is indicated for the treatment of mildly symptomatic COVID-19 outpatients who are at high risk of progressing to moderate or severe disease. St. Luke's network offers outpatient infusions of casirivimab/imdevimab and sotrovimab at St. Luke's Des Peres Hospital. (This page updated 1/5/2022)

The attached physician packet contains all the needed documentation to screen, educate, consent, and schedule your qualifying patient for Outpatient Monoclonal Infusion Therapy at St. Luke's Des Peres Hospital. It includes:
  • Monoclonal Antibody Information Sheet
  • Talking Points for Ordering Physicians
  • Screening Questions and Order Form
  • EUA Fact Sheets for Patients and Caregivers
  • Informed Consent Form
  • Patient Brochure
For more information, call 314-966-9463.

Download the Entire
Physician Packet (PDF)
Download Order Form
and Consent ONLY (PDF)